全文获取类型
收费全文 | 1155篇 |
免费 | 99篇 |
国内免费 | 24篇 |
专业分类
耳鼻咽喉 | 28篇 |
儿科学 | 55篇 |
妇产科学 | 19篇 |
基础医学 | 120篇 |
口腔科学 | 48篇 |
临床医学 | 123篇 |
内科学 | 222篇 |
皮肤病学 | 29篇 |
神经病学 | 45篇 |
特种医学 | 232篇 |
外国民族医学 | 1篇 |
外科学 | 73篇 |
综合类 | 44篇 |
一般理论 | 1篇 |
预防医学 | 109篇 |
眼科学 | 9篇 |
药学 | 58篇 |
肿瘤学 | 62篇 |
出版年
2019年 | 7篇 |
2018年 | 15篇 |
2017年 | 10篇 |
2016年 | 16篇 |
2015年 | 12篇 |
2014年 | 21篇 |
2013年 | 26篇 |
2012年 | 25篇 |
2011年 | 38篇 |
2010年 | 32篇 |
2009年 | 39篇 |
2008年 | 43篇 |
2007年 | 32篇 |
2006年 | 34篇 |
2005年 | 23篇 |
2004年 | 37篇 |
2003年 | 36篇 |
2002年 | 23篇 |
2001年 | 22篇 |
2000年 | 19篇 |
1999年 | 27篇 |
1998年 | 46篇 |
1997年 | 47篇 |
1996年 | 48篇 |
1995年 | 38篇 |
1994年 | 26篇 |
1993年 | 36篇 |
1992年 | 30篇 |
1991年 | 21篇 |
1990年 | 17篇 |
1989年 | 33篇 |
1988年 | 37篇 |
1987年 | 52篇 |
1986年 | 29篇 |
1985年 | 18篇 |
1984年 | 12篇 |
1983年 | 14篇 |
1982年 | 19篇 |
1981年 | 27篇 |
1980年 | 20篇 |
1979年 | 10篇 |
1978年 | 9篇 |
1977年 | 12篇 |
1976年 | 24篇 |
1975年 | 12篇 |
1973年 | 7篇 |
1972年 | 8篇 |
1934年 | 6篇 |
1933年 | 6篇 |
1930年 | 6篇 |
排序方式: 共有1278条查询结果,搜索用时 9 毫秒
101.
102.
103.
104.
105.
Familial amyloidotic patients' experience of the disease and of liver transplantation 总被引:1,自引:0,他引:1
Elisabeth Jonsèn RNT Elsy Athlin RNT DR.med.sci. & Ole Suhr MD PhD 《Journal of advanced nursing》1998,27(1):52-58
Liver transplantation is a new treatment for familial amyloidotic polyneuropathy (FAP). No qualitative study examining these patients' experiences of the disease and the treatment has been published. The purpose of this study was to explore and describe the experience of the disease and the liver transplantation from the FAP patient's perspective. In-depth interviews with 11 liver transplant FAP patients were performed. The process of the FAP disease and a liver transplantation was found to involve the following categories: going downhill, defence and denial, a chance of surviving, the decision — no choice, waiting powerless and uncertain, the first few steps after surgery, freed from the death sentence, still disabled, mastering up strength to recover, and the need for support and help. 相似文献
106.
目的:低白蛋白血症是肝移植患者的常见并发症,也是患者预后的重要影响因素。肝移植术后选择合理的白蛋白应用方案将有益于提高肝移植患者术后近远期疗效。方法:选择2000-10/2005-06于北京大学第三医院行肝移植并且随访时间大于6个月的患者80例,对治疗方案均知情同意。医院自2003年8月开始改变了肝移植术后白蛋白的输入方案:①方案改变之前患者即白蛋白输入方案未改变组(n=50),术后早期常规输入白蛋白剂量大于60g/d。②方案改变之后患者即白蛋白输入方案改变组(n=30),适当减少术后早期白蛋白输入的常规剂量至0 ̄20g/d。统计分析两组患者的一般情况、术后白蛋白使用情况、预后情况及住院费用。另外,对于两组中术后存在低白蛋白相关严重并发症的患者进行进一步的比较分析。结果:80例患者全部进入结果分析。①两组患者术前及术中一般情况差异无显著性意义(P>0.05)。②白蛋白输入方案改变组术后早期白蛋白的使用量及其费用/总住院费用比例显著低于白蛋白输入方案未改变组(P<0.01)。但两组患者术后第3天肝功能情况、白蛋白水平、早期并发症发生率、早期死亡率、半年生存率及呼吸机时间等情况差异均无显著性意义(P>0.05)。③两组中术后出现低白蛋白相关严重并发症患者术后第3天肝功能情况、白蛋白水平、早期死亡率、半年生存率及呼吸机应用时间等情况差异均无显著性意义(P>0.05)。结论:肝移植术后过多输入白蛋白不能改善患者预后;适当减少术后白蛋白的常规输入剂量,同时根据血白蛋白水平及并发症情况随时调整白蛋白的输入量能够减少白蛋白的用量,对患者预后因素亦无明显影响。 相似文献
107.
Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese hamster ovary cells. 总被引:15,自引:3,他引:15 下载免费PDF全文
N Ferrara J Winer T Burton A Rowland M Siegel H S Phillips T Terrell G A Keller A D Levinson 《The Journal of clinical investigation》1993,91(1):160-170
Vascular endothelial growth factor (VEGF) is a mitogen with a specificity for endothelial cells in vitro and an angiogenic inducer in vivo. We tested the hypothesis that VEGF may confer on expressing cells a growth advantage in vivo. Dihydrofolatereductase--Chinese hamster ovary cells were transfected with expression vectors which direct the constitutive synthesis of VEGF. Neither the expression nor the exogenous administration of VEGF stimulated anchorage-dependent or anchorage-independent growth of Chinese hamster ovary cells in vitro. However, VEGF-expressing clones, unlike control cells, demonstrated an ability to proliferate in nude mice. Histologic examination revealed that the proliferative lesions were compact, well vascularized, and nonedematous. Ultrastructural analysis revealed that capillaries within the lesions were of the continuous type. These findings indicate that the expression of VEGF may confer on cells the ability to grow in vivo in the absence of transformation by purely paracrine mechanisms. Since VEGF is a widely distributed protein, this property may have relevance for a variety of physiological and pathological proliferative processes. 相似文献
108.
Diabetic retinopathy: a leading cause of new blindness 总被引:1,自引:0,他引:1
Some of the basic underlying processes in the development of diabetic retinopathy include changes in the walls of retinal vessels, with occlusion and leakage. These result in edema, hemorrhage, hard exudates, plaques, and ischemia, leading to neovascularization. When proliferative retinopathy supervenes, it may result in complete blindness. Internists and family practice physicians should be alert for early signs of diabetic retinopathy. Ideally, diabetic patients should have their eyes examined yearly by an ophthalmologist. A fundus examination without dilation and usually without acuity testing rarely detects proliferative or early background retinopathy. Multicenter studies have shown that photocoagulation of new vessels with the argon laser may significantly reduce the incidence of severe visual loss. This treatment method has the potential of reducing the incidence of diabetic blindness by 60% to 80%. Photocoagulation is not a "cure" for diabetic macular edema; when used judiciously, however, it can sometimes further reduce visual loss caused by this common disease. The course of diabetic retinopathy in individual cases is unpredictable. After photocoagulation, some patients cannot see as well as before, though in others the progress of the disease is arrested. There is a conservative concern about a procedure that destroys retinal tissue in the hope of limiting the progression of the disorder. Yet photocoagulation appears to be the only alternative until a better treatment is developed through basic research. 相似文献
109.
Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis 总被引:5,自引:0,他引:5
Zhao MH; Jayne DR; Ardiles LG; Culley F; Hodson ME; Lockwood CM 《QJM : monthly journal of the Association of Physicians》1996,89(4):259-265
Cystic fibrosis (CF), a genetic disorder, is characterized by chronic
pulmonary infection/inflammation which leads to respiratory failure. The
presence of anti-neutrophil cytoplasmic autoantibodies (ANCA) has
previously been observed in the sera of patients with CF. In view of the
known relationship of ANCA with primary vasculitis and of their putative
pathogenetic role in these disorders, we studied the presence, specificity
and isotype of ANCA and their clinical associations in 66 adult CF
patients. None of the 66 CF samples had autoantibodies to the major ANCA
antigens, proteinase 3 or myeloperoxidase. However, 60/66 (91%) CF samples
contained IgG and 55/66 (83%) IgA, autoantibodies to
bactericidal/permeability increasing protein (BPI), a recently
characterized ANCA specificity. All the IgA anti-BPI-positive samples were
also IgG anti-BPI-positive. The autoantibody specificity was confirmed by
inhibition assay and immunoblotting of CF sera against a neutrophil granule
preparation. Furthermore, in this cross-sectional study, anti-BPI levels
were inversely correlated with the observed reductions in FEV1 and FVC (IgA
anti-BPI and FEV1: r = 0.508, <it>p</it> < 0.0001), and
both IgG and IgA anti-BPI levels were higher in CF patients with secondary
vasculitis (<it>n</it> = 6) than in those without
(<it>p</it> < 0.05). ANCA with specificity for BPI were
present in the majority of CF sera in this study and autoimmune processes
may be associated with the development of pulmonary injury in CF.
相似文献
110.
Stanworth SJ; Bhavnani M; Chattopadhya C; Miller H; Swinson DR 《QJM : monthly journal of the Association of Physicians》1998,91(1):49-56
Felty's syndrome (FS) (rheumatoid arthritis with neutropenia and
splenomegaly) has a poor prognosis, largely because of the high risk of
severe infection. Granulocyte colony-stimulating factor (G-CSF) is an
emerging treatment for chronic neutropenia. We prospectively monitored its
use in eight patients with recurrent infections or who required joint
surgery. Significant side-effects were documented in five, including
nausea, malaise, generalized joint pains, and in one patient, a vasculitic
skin rash. In two patients treatment had to be stopped, and in these cases
G-CSF had been started at full vial dosage (300 micrograms/ml filgrastim or
263 micrograms/ml lenograstim) alternate days or daily. G-CSF treatment was
continued in three patients by restarting at reduced dose, and changing the
proprietary formulation. G- CSF raised the neutrophil count, reduced severe
infection, and allowed surgery to be performed. A combined clinical and
laboratory index suggested that long-term treatment (up to 3.5 years) did
not exacerbate the arthritis. Once on established treatment, it may be
possible to use smaller weekly doses of G-CSF to maintain the same clinical
benefit. One of the three patients whose FS was associated with a large
granular T-cell lymphocytosis showed a reduction in this subset of
lymphocytes during G-CSF treatment.
相似文献